We are live on ! Find out more
PCSA icon

Processa Pharmaceuticals
PCSA

18 hedge funds and large institutions have $3.24M invested in Processa Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

13% more funds holding

Funds holding: 16 → 18 (+2)

1% more capital invested

Capital invested by funds: $3.22M → $3.24M (+$18K)

0% more ownership

Funds ownership: 0.01% → 0.01% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
18
Holders Change
+2
Holders Change %
+12.5%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$134K
2
CBA
Coastal Bridge Advisors
Connecticut
+$54.8K
3
Renaissance Technologies
Renaissance Technologies
New York
+$31.5K
4
VRM
Vectors Research Management
New York
+$11K
5
EIM
Essex Investment Management
Massachusetts
+$6.85K

Top Sellers

Rank Fund Capital Flow
1
SCM
Solas Capital Management
Connecticut
-$69K
2
TRCT
Tower Research Capital (TRC)
New York
-$4.11K
3
UBS Group
UBS Group
Switzerland
-$3K
4
BlackRock
BlackRock
New York
-$1.37K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.05M – – –
ACM
2
AIGH Capital Management
Maryland
$853K – – –
WVP
3
Worth Venture Partners
New Jersey
$251K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$182K – – –
VCA
5
Verdence Capital Advisors
Maryland
$168K – – –
CBA
6
Coastal Bridge Advisors
Connecticut
$148K +$54.8K +40 +62%
Morgan Stanley
7
Morgan Stanley
New York
$138K +$134K +98 New
Janney Montgomery Scott
8
Janney Montgomery Scott
Pennsylvania
$135K – – –
State Street
9
State Street
Massachusetts
$120K +$4.11K +3 +4%
BlackRock
10
BlackRock
New York
$81K -$1.37K -1 -2%
Northern Trust
11
Northern Trust
Illinois
$43K – – –
Renaissance Technologies
12
Renaissance Technologies
New York
$33K +$31.5K +23 New
VRM
13
Vectors Research Management
New York
$11K +$11K +8 New
Wells Fargo
14
Wells Fargo
California
$9K – – –
EIM
15
Essex Investment Management
Massachusetts
$6K +$6.85K +5 New
AF
16
Allworth Financial
California
$5K – – –
TRCT
17
Tower Research Capital (TRC)
New York
$4K -$4.11K -3 -50%
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
$3K – – –
SCM
19
Solas Capital Management
Connecticut
– -$69K -46 Closed
UBS Group
20
UBS Group
Switzerland
– -$3K -2 Closed

PCSA Hedge Fund Activity: Q2 2022 in Review

18 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q2 2022, worth a combined $3.24M — up 0.56% from $3.22M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new PCSA positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Morgan Stanley, opening a new position worth an estimated $134K. The largest seller was Solas Capital Management, exiting entirely with an estimated $69K sold.

  • 18 institutional investors held Processa Pharmaceuticals (PCSA) as of Q2 2022, up from 16 in Q1 2022.
  • Funds reported $3.24M of Processa Pharmaceuticals stock for Q2 2022, up 0.56% quarter-over-quarter.
  • 4 funds opened new Processa Pharmaceuticals positions in Q2 2022 and 2 closed out, a net change of +2 holders.
  • The largest Processa Pharmaceuticals buyer in Q2 2022 was Morgan Stanley, an estimated $134K added.
  • The largest Processa Pharmaceuticals seller in Q2 2022 was Solas Capital Management, an estimated $69K sold.

Based on aggregated 13F filings for Q2 2022.